Design, Synthesis, and Actions of a Novel Chimeric Natriuretic Peptide: CD-NP

Ondrej Lisy, Brenda K. Huntley, Daniel J Mc Cormick, Paul A. Kurlansky, John C Jr. Burnett

Research output: Contribution to journalArticle

120 Citations (Scopus)

Abstract

Objectives: Our aim was to design, synthesize and test in vivo and in vitro a new chimeric peptide that would combine the beneficial properties of 2 distinct natriuretic peptides with a biological profile that goes beyond native peptides. Background: Studies have established the beneficial vascular and antiproliferative properties of C-type natriuretic peptide (CNP). While lacking renal actions, CNP is less hypotensive than the cardiac peptides atrial natriuretic peptide and B-type natriuretic peptide but unloads the heart due to venodilation. Dendroaspis natriuretic peptide is a potent natriuretic and diuretic peptide that is markedly hypotensive and functions via a separate guanylyl cyclase receptor compared with CNP. Methods: Here we engineered a novel chimeric peptide CD-NP that represents the fusion of the 22-amino acid peptide CNP together with the 15-amino acid linear C-terminus of Dendroaspis natriuretic peptide. We also determined in vitro in cardiac fibroblasts cyclic guanosine monophosphate-activating and antiproliferative properties of CD-NP. Results: Our studies demonstrate in vivo that CD-NP is natriuretic and diuretic, glomerular filtration rate enhancing, cardiac unloading, and renin inhibiting. CD-NP also demonstrates less hypotensive properties when compared with B-type natriuretic peptide. In addition, CD-NP in vitro activates cyclic guanosine monophosphate and inhibits cardiac fibroblast proliferation. Conclusions: The current findings advance an innovative design strategy in natriuretic peptide drug discovery and development to create therapeutic peptides with favorable properties that may be preferable to those associated with native natriuretic peptides.

Original languageEnglish (US)
Pages (from-to)60-68
Number of pages9
JournalJournal of the American College of Cardiology
Volume52
Issue number1
DOIs
StatePublished - Jul 1 2008

Fingerprint

C-Type Natriuretic Peptide
Natriuretic Peptides
Peptides
Brain Natriuretic Peptide
Cyclic GMP
Diuretics
Guanylate Cyclase-Coupled Receptors
Fibroblasts
Amino Acids
Atrial Natriuretic Factor
Drug Discovery
Glomerular Filtration Rate
Renin
Blood Vessels
CD-NP natriuretic peptide
Kidney
In Vitro Techniques
Dendroaspis natriuretic peptide

Keywords

  • blood pressure
  • cGMP
  • fibroblasts
  • kidney
  • peptide
  • sodium excretion

ASJC Scopus subject areas

  • Nursing(all)

Cite this

Design, Synthesis, and Actions of a Novel Chimeric Natriuretic Peptide : CD-NP. / Lisy, Ondrej; Huntley, Brenda K.; Mc Cormick, Daniel J; Kurlansky, Paul A.; Burnett, John C Jr.

In: Journal of the American College of Cardiology, Vol. 52, No. 1, 01.07.2008, p. 60-68.

Research output: Contribution to journalArticle

@article{94306d975c684808bafa3d3e7632f7d2,
title = "Design, Synthesis, and Actions of a Novel Chimeric Natriuretic Peptide: CD-NP",
abstract = "Objectives: Our aim was to design, synthesize and test in vivo and in vitro a new chimeric peptide that would combine the beneficial properties of 2 distinct natriuretic peptides with a biological profile that goes beyond native peptides. Background: Studies have established the beneficial vascular and antiproliferative properties of C-type natriuretic peptide (CNP). While lacking renal actions, CNP is less hypotensive than the cardiac peptides atrial natriuretic peptide and B-type natriuretic peptide but unloads the heart due to venodilation. Dendroaspis natriuretic peptide is a potent natriuretic and diuretic peptide that is markedly hypotensive and functions via a separate guanylyl cyclase receptor compared with CNP. Methods: Here we engineered a novel chimeric peptide CD-NP that represents the fusion of the 22-amino acid peptide CNP together with the 15-amino acid linear C-terminus of Dendroaspis natriuretic peptide. We also determined in vitro in cardiac fibroblasts cyclic guanosine monophosphate-activating and antiproliferative properties of CD-NP. Results: Our studies demonstrate in vivo that CD-NP is natriuretic and diuretic, glomerular filtration rate enhancing, cardiac unloading, and renin inhibiting. CD-NP also demonstrates less hypotensive properties when compared with B-type natriuretic peptide. In addition, CD-NP in vitro activates cyclic guanosine monophosphate and inhibits cardiac fibroblast proliferation. Conclusions: The current findings advance an innovative design strategy in natriuretic peptide drug discovery and development to create therapeutic peptides with favorable properties that may be preferable to those associated with native natriuretic peptides.",
keywords = "blood pressure, cGMP, fibroblasts, kidney, peptide, sodium excretion",
author = "Ondrej Lisy and Huntley, {Brenda K.} and {Mc Cormick}, {Daniel J} and Kurlansky, {Paul A.} and Burnett, {John C Jr.}",
year = "2008",
month = "7",
day = "1",
doi = "10.1016/j.jacc.2008.02.077",
language = "English (US)",
volume = "52",
pages = "60--68",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Design, Synthesis, and Actions of a Novel Chimeric Natriuretic Peptide

T2 - CD-NP

AU - Lisy, Ondrej

AU - Huntley, Brenda K.

AU - Mc Cormick, Daniel J

AU - Kurlansky, Paul A.

AU - Burnett, John C Jr.

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Objectives: Our aim was to design, synthesize and test in vivo and in vitro a new chimeric peptide that would combine the beneficial properties of 2 distinct natriuretic peptides with a biological profile that goes beyond native peptides. Background: Studies have established the beneficial vascular and antiproliferative properties of C-type natriuretic peptide (CNP). While lacking renal actions, CNP is less hypotensive than the cardiac peptides atrial natriuretic peptide and B-type natriuretic peptide but unloads the heart due to venodilation. Dendroaspis natriuretic peptide is a potent natriuretic and diuretic peptide that is markedly hypotensive and functions via a separate guanylyl cyclase receptor compared with CNP. Methods: Here we engineered a novel chimeric peptide CD-NP that represents the fusion of the 22-amino acid peptide CNP together with the 15-amino acid linear C-terminus of Dendroaspis natriuretic peptide. We also determined in vitro in cardiac fibroblasts cyclic guanosine monophosphate-activating and antiproliferative properties of CD-NP. Results: Our studies demonstrate in vivo that CD-NP is natriuretic and diuretic, glomerular filtration rate enhancing, cardiac unloading, and renin inhibiting. CD-NP also demonstrates less hypotensive properties when compared with B-type natriuretic peptide. In addition, CD-NP in vitro activates cyclic guanosine monophosphate and inhibits cardiac fibroblast proliferation. Conclusions: The current findings advance an innovative design strategy in natriuretic peptide drug discovery and development to create therapeutic peptides with favorable properties that may be preferable to those associated with native natriuretic peptides.

AB - Objectives: Our aim was to design, synthesize and test in vivo and in vitro a new chimeric peptide that would combine the beneficial properties of 2 distinct natriuretic peptides with a biological profile that goes beyond native peptides. Background: Studies have established the beneficial vascular and antiproliferative properties of C-type natriuretic peptide (CNP). While lacking renal actions, CNP is less hypotensive than the cardiac peptides atrial natriuretic peptide and B-type natriuretic peptide but unloads the heart due to venodilation. Dendroaspis natriuretic peptide is a potent natriuretic and diuretic peptide that is markedly hypotensive and functions via a separate guanylyl cyclase receptor compared with CNP. Methods: Here we engineered a novel chimeric peptide CD-NP that represents the fusion of the 22-amino acid peptide CNP together with the 15-amino acid linear C-terminus of Dendroaspis natriuretic peptide. We also determined in vitro in cardiac fibroblasts cyclic guanosine monophosphate-activating and antiproliferative properties of CD-NP. Results: Our studies demonstrate in vivo that CD-NP is natriuretic and diuretic, glomerular filtration rate enhancing, cardiac unloading, and renin inhibiting. CD-NP also demonstrates less hypotensive properties when compared with B-type natriuretic peptide. In addition, CD-NP in vitro activates cyclic guanosine monophosphate and inhibits cardiac fibroblast proliferation. Conclusions: The current findings advance an innovative design strategy in natriuretic peptide drug discovery and development to create therapeutic peptides with favorable properties that may be preferable to those associated with native natriuretic peptides.

KW - blood pressure

KW - cGMP

KW - fibroblasts

KW - kidney

KW - peptide

KW - sodium excretion

UR - http://www.scopus.com/inward/record.url?scp=45449110992&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45449110992&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2008.02.077

DO - 10.1016/j.jacc.2008.02.077

M3 - Article

C2 - 18582636

AN - SCOPUS:45449110992

VL - 52

SP - 60

EP - 68

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 1

ER -